Specialty drugs
Here's the statistic that reframes everything: specialty drugs are only about 2% of prescriptions but roughly half of all US drug spending. If you want to understand where the money actually goes, this is the category to understand.
There's no single official definition
“Specialty” isn't an FDA category — it's a label payers use, and the lines are fuzzy. But a drug usually earns it by having several of these traits:
- High cost — often thousands of dollars a month. Medicare's Part D specialty tier kicks in around $950 a month; many specialty drugs cost far more.
- Complex to make and take — frequently biologics, injected or infused rather than swallowed.
- Special handling — refrigeration or a cold chain, careful storage, short shelf life.
- Special monitoring — lab work, dose titration, or risk-management programs to use safely.
- Complex or rare conditions — cancer, autoimmune diseases, multiple sclerosis, HIV, hepatitis C, and rare (“orphan”) diseases.
See it in the data
Look at the top of our Medicaid spend list: Biktarvy (HIV), Humira and Stelara (autoimmune), Dupixent, Ozempic. Almost every drug at the top is specialty. A handful of products drive an outsized share of the entire program's spending.
Why they dominate spend
It's simple math with a lopsided distribution. A specialty drug can cost 50 to 500 times what a common generic costs per prescription. So even though very few patients take them, they swamp the totals. And the mix keeps shifting toward specialty: the industry pipeline is now dominated by biologics, gene therapies, and cell therapies — some of which carry one-time price tags in the millions.
Why they cost so much
- Hard to manufacture: growing a biologic in living cells is expensive and unforgiving, in a way pressing a tablet never is.
- Small patient populations: an orphan drug's development cost is spread across very few patients, and orphan status brings extra exclusivity.
- Little competition: many specialty drugs are the only option for their condition, and biologics resist cheap copying — so there's no generic-style price collapse to pull prices down.
They're priced and delivered through a different channel
Specialty drugs often bypass the corner pharmacy entirely. They flow through specialty pharmacies (frequently owned by the same PBMs that run the benefit), through limited distribution networks where only a few pharmacies are allowed to dispense a product, and — for clinic-infused drugs — through Medicare Part B's ASP + 6%“buy-and-bill” model rather than a pharmacy counter. Nearly every specialty script also passes through prior authorization, the payer's gate before it will cover the cost.
Why it matters
Specialty drugs are where cost, complexity, and access pressure all concentrate — and where biosimilar competition and rebate dynamics matter most, because the dollars are so large. Watching the highest-spend drugs is watching the specialty market.